NCT00553267已完成3 期
An Eight-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 40mg + Amlodipine 10mg Versus Telmisartan 80mg + Amlodipine 10mg Versus Amlodipine 10mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 10mg Monotherapy
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 947
- 试验地点
- 141
- 主要终点
- Change From Baseline in Trough Seated Diastolic Blood Pressure
研究概览
简要总结
The primary objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40mg + amlodipine 10mg (T40/A10) or the fixed dose combination of telmisartan 80mg + amlodipine 10mg (T80/A10) is superior in reducing blood pressure at eight weeks compared with amlodipine 10mg monotherapy (A10) in patients who fail to respond to six weeks treatment with A10.
研究设计
- 研究类型
- Interventional
- 干预模型
- Parallel
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •diagnosis of essential hypertension and blood pressure not adequately controlled before informed consent (inadequate control defined as seated diastolic blood pressure (DBP) >= 95 mmHg if on existing antihypertensive treatment or seated DBP >= 100 mmHg if treatment-naïve).
- •failure to respond to six weeks treatment with amlodipine 10mg. (Failure to respond defined as seated DBP >= 90 mmHg.)
- •able to stop any current antihypertensive therapy without unacceptable risk to the patient.
- •willing and able to provide written informed consent.
排除标准
- •pregnancy, breast-feeding, unwilling to use effective contraception (if female of child-bearing potential).
- •known or suspected secondary hypertension.
- •mean seated systolic blood pressure (SBP) >=200 mmHg and/or mean seated DBP >= 120 mmHg during run-in treatment or mean seated SBP >= 180 mmHg and/or mean seated DBP >= 120 mmHg at the randomisation visit or at any time during randomised treatment.
- •any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant.
- •clinically relevant hyperkalaemia.
- •uncorrected volume or sodium depletion.
- •primary aldosteronism.
- •hereditary fructose or lactose intolerance.
- •symptomatic congestive heart failure.
- •patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or ARBs.
- •history of drug or alcohol dependency within the six months prior to signing consent.
- •concurrent participation in another clinical trial or any investigational therapy within thirty days prior to signing consent.
- •hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve.
- •known allergic hypersensitivity to any component of the formulations under investigation. (Includes known hypersensitivity to telmisartan or other ARBs or amlodipine or other dihydropyridine CCBs.)
- •non-compliance with study medication (defined as less than 80% or more than 120%) during the open-label run-in treatment period.
- •current treatment with any antihypertensive agents, whether or not prescribed for this indication, that cannot be safely stopped (investigator¿s decision) by the start of the run-in period.
- •chronic administration of any medication known to affect blood pressure, other than the trial medication.
- •any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine.
结局指标
主要结局
Change From Baseline in Trough Seated Diastolic Blood Pressure
时间窗: Baseline and end of study (8 weeks or last value on treatment)
Change from baseline to the end of study in trough DBP
次要结局
- Change From Baseline in Trough Seated Systolic Blood Pressure(Baseline and end of study (8 weeks or last value on treatment))
- Trough Seated Diastolic Blood Pressure Control (Defined as < 90mmHg)(End of study (8 weeks or last value on treatment))
- Trough Seated Diastolic Blood Pressure <80 mmHg(End of study (8 weeks or last value on treatment))
- Trough Seated DBP Response(End of study (8 weeks or last value on treatment))
- Trough Seated SBP Control(End of study (8 weeks or last value on treatment))
- Trough Seated BP Normality Classes(End of study (8 weeks or last value on treatment))
- Oedema Incidence Rate(During randomised treatment period)
- Peripheral Oedema Incidence Rate(During randomised treatment period)
- Trough Seated SBP Response(End of study (8 weeks or last value on treatment))
研究者
研究点 (141)
Loading locations...
相似试验
已完成
3 期
An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 MonotherapyHypertensionNCT01103960Boehringer Ingelheim324
已完成
3 期
Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5HypertensionNCT00239369Boehringer Ingelheim713
已完成
3 期
Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan MonotherapyHypertensionNCT00144222Boehringer Ingelheim218
已完成
4 期
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 HypertensionHypertensionNCT00168779Boehringer Ingelheim1,185
终止
4 期
SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk PatientsCoronary ArteriosclerosisHypertensionNCT00274105Boehringer Ingelheim22